Ginkgo Bioworks Slips 2.57% as Investors Await Earnings
The stock fell while Zacks’ estimates pointed to lower quarterly revenue and a smaller loss compared with the year-earlier period.
Makkler Newsroom · Oct 2, 01:56 AM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $8.00 (-16.8%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.